8-KEarnings & ResultsExhibits & Filings

IDEXX LABORATORIES INC /DE 8-K Report, Financial Results (Jul 27, 2007)

Filed July 27, 2007For Securities:IDXX

Summary

IDEXX Laboratories, Inc. (IDXX) filed a Form 8-K on July 27, 2007, to report its financial results for the quarter ended June 30, 2007. This filing primarily serves to furnish a press release announcing these results. While the filing itself does not contain detailed financial figures, it directs investors to an attached press release (Exhibit 99.1) for the specific operational and financial performance data of the second quarter of 2007. Investors should refer to the furnished press release for comprehensive information regarding IDEXX's performance, including key metrics, earnings per share, revenue, and any forward-looking guidance or management commentary. The 8-K filing itself confirms the date of the announcement and the availability of the detailed financial report.

Key Highlights

  • 1IDEXX Laboratories filed an 8-K on July 27, 2007, to report its Q2 2007 financial results.
  • 2The primary purpose of the filing is to furnish a press release detailing the financial outcomes.
  • 3Investors should consult Exhibit 99.1 (the press release) for specific financial data and operational performance.
  • 4The report confirms the announcement date of the second quarter results as July 27, 2007.
  • 5The filing itself does not contain the detailed financial results but references the external press release.

Frequently Asked Questions

The main purpose of this 8-K filing is to officially report and furnish the press release containing IDEXX Laboratories' financial results for the quarter ended June 30, 2007.

The detailed financial results are provided in the press release titled "IDEXX Laboratories Announces Second Quarter Results," which is furnished as Exhibit 99.1 to this Form 8-K filing.

No, the information furnished in this Form 8-K under Item 2.02, including the press release, is not deemed 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934, nor is it subject to the liabilities of that section unless expressly incorporated by reference into another filing.

The report was signed by Merilee Raines, Corporate Vice President and Chief Financial Officer, on behalf of IDEXX Laboratories, Inc.